SCHEMBL31677834

SCHEMBL31677834

C=CS(=O)(=O)Nc1ccccc1-c1c(C)n(CC(=O)Nc2ccc(F)cc2)c2nc(CC)c(-c3ccccc3)c(=O)n12

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ KMT2A Q03164 4/20 0.37
▸ MEN1 O00255 3/20 0.37
▸ ACHE P22303 1/20 0.37
▸ BACE1 P56817 1/20 0.37
▸ MAPT P10636 5/20 0.36
▸ POLB P06746 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ ALDH1A1 P00352 3/20 0.36
▸ HPGD P15428 2/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.35
▸ PPARG P37231 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31677686 0.89 RORC (0.39) KDM4ESMN1; SMN2KMT2AMEN1ACHE
SCHEMBL31678821 0.87 KDM4E (0.38) KDM4ESMN1; SMN2KMT2AMEN1ACHE
SCHEMBL31677890 0.84 ACHE (0.41) KDM4ESMN1; SMN2KMT2AMEN1ACHE
SCHEMBL31678128 0.79 ACHE (0.45) KDM4ESMN1; SMN2KMT2AMEN1ACHE
SCHEMBL31677853 0.78 KDM4E (0.42) KDM4ESMN1; SMN2KMT2AMEN1MAPT
SCHEMBL31653818 0.77 MAPT (0.40) KDM4ESMN1; SMN2KMT2AMAPTPOLB
SCHEMBL31678860 0.76 RORC (0.39) KDM4ESMN1; SMN2KMT2AMEN1ACHE
SCHEMBL31677840 0.76 MAPT (0.39) KDM4EKMT2AMEN1MAPTPOLB
SCHEMBL31653694 0.75 POLB (0.35) KDM4EKMT2AMEN1MAPTPOLB
SCHEMBL31653824 0.73 KDM4E (0.46) KDM4ESMN1; SMN2KMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250270217-A1 IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES HAVING A COVALENT WARHEAD AT THE 3-POSITION AS WRN INHIBITORS INCYTE CORPORATION (US) 2025-08-28 — — US claimed
US-20250270217-A1 IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES HAVING A COVALENT WARHEAD AT THE 3-POSITION AS WRN INHIBITORS INCYTE CORPORATION (US) 2025-08-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250270217-A1 IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES HAVING A COVALENT WARHEAD AT THE 3-POSITION AS WRN INHIBITORS WRN, RECQL, BLM KDM4E 2390/4885SMN1; SMN2 2576/4885KMT2A 1697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback